I

Iambic Therapeutics

AI-driven discovery for oncology and neurology

Machine Learning Scientist - Large Multimodal Models, Post-Training

Full-Time
No salary listed
Entry, Junior, Mid
PhD
Bristol, UK
RemoteRemote position with an option to work on-site in the Bristol office.
AI & Machine LearningAI Research

About the job

Requirements
  • A PhD in machine learning, computer science, computational chemistry, physics, or a related computational STEM field, or equivalent industry experience demonstrating comparable depth.
  • Strong Python and PyTorch skills, including implementing, training, debugging, and evaluating deep learning models end-to-end.
  • Demonstrated experience training large-scale transformer models.
  • Experience with reinforcement learning approaches such as RLHF, RLAIF, PPO, GRPO, reinforcement learning with verifiable rewards, or related methods.
  • Experience with supervised fine-tuning, full-parameter fine-tuning, parameter-efficient fine-tuning such as LoRA, or related methods.
  • Experience with systematic hyperparameter optimization or large-scale experimentation using tools such as Optuna, Ray Tune, or similar frameworks.
  • Strong engineering practices involving reproducible experimentation, clean code, testing, and performance-aware debugging.
  • Comfort with modern machine learning infrastructure such as Docker, CUDA, Kubernetes, and experiment-tracking tools such as Weights & Biases.
Responsibilities
  • Research and develop post-training strategies for large-scale multimodal foundation models.
  • Design reward functions, training objectives, data-generation strategies, and evaluation protocols for reinforcement learning and other post-training approaches applied to multimodal large language models.
  • Build systematic experimentation and hyperparameter-optimization workflows to efficiently explore post-training recipes, model configurations, and training strategies.
  • Develop and apply inference-optimization techniques to support deployment in high-throughput model evaluation and interactive discovery workflows.
  • Design and maintain rigorous benchmarking and evaluation frameworks that measure model quality across modalities, downstream tasks, and scientific use cases.
  • Collaborate with machine learning and software engineering colleagues to productionize models, evaluation systems, and inference services.
  • Partner with computational chemists, medicinal chemists, and biologists to ensure model development and post-training objectives are grounded in drug-discovery needs.
  • Communicate results to internal teams, external partners, and at conferences.
  • Write, refactor, test, document, and package high-quality research and engineering code and machine-learning components.
Desired Qualifications
  • Experience with multimodal or multi-task model architectures.
  • Experience with training and inference optimization, including mixed precision, kernel optimization, quantization, and distributed strategies.
  • Familiarity with biomedical, chemical, or biological data domains.
  • Experience with distributed training at scale.
  • HPC or large-scale training-operations experience.

About the company

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$303M

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Iambic filed an IPO on September 21, 2026, after $207.9 million cash.
  • Revenues reached $18 million over the twelve months ended June 30, 2026.
  • ClinicalTrials.gov shows IAM1363 recruiting 383 patients across 53 sites, including EU expansion.

What critics are saying

  • IAM1363 remains unproven; Phase 1 completion sits in 2028, delaying any approval.
  • Iambic's revenue still depends on partnerships; AbbVie and IPO proceeds fund the burn.
  • If AbbVie walks and IAM1363 fails, Iambic becomes a platform story without assets.

What makes Iambic Therapeutics unique

  • Enchant v3 spans 6,000+ molecular properties across 16 modalities, compressing discovery cycles.
  • AbbVie's September 21, 2026 collaboration validates Iambic's platform with another pharma heavyweight.
  • IAM1363 reached Phase 1 from AI design, proving platform-to-clinic execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-3%
Intelligence360
Oct 5th, 2026
Iambic Therapeutics raises $66.5M to advance AI-driven drug discovery platform

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission to raise $66.5 million in new funding. The filing was made under Regulation D or Section 4(a)(5) of the Securities Act of 1933, which allows companies to sell securities without registration. Iambic Therapeutics is a drug discovery company that uses AI and automated chemistry and biology experimentation to accelerate pharmaceutical development. The company's platform integrates proprietary AI technologies, including Enchant and NeuralPLexer, for multimodal endpoint prediction. The company previously advanced a novel drug candidate to clinical trials in approximately two years and maintains a diverse preclinical pipeline. Iambic is led by Chief Executive Officer Tom Miller.

PR Newswire
Sep 21st, 2026
AbbVie partners with Iambic to accelerate AI-driven drug discovery in immunology, neuroscience and oncology

AbbVie and Iambic Therapeutics have entered into a multi-year collaboration to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology. The partnership will combine Iambic's molecular superintelligence platform with AbbVie's therapeutic expertise to develop small molecule therapies with first-in-class and best-in-class potential. The collaboration will utilise Enchant v3, Iambic's next-generation multimodal transformer model trained on over 6,000 molecular properties. This technology is designed to optimise candidate properties simultaneously, reducing drug discovery timelines whilst improving success rates. Under the agreement, Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated through the collaboration. The partnership aims to accelerate the discovery process and deliver breakthrough medicines to patients more quickly.

Associated Press
Sep 21st, 2026
Iambic unveils Enchant v3 AI model with 41B parameters to accelerate drug discovery

Iambic, a clinical-stage life science and technology company, has launched Enchant v3, the latest version of its AI-driven multimodal transformer model for drug discovery and development. The model features 41 billion parameters and has been pretrained on 4.5 trillion tokens. Enchant v3 can predict more than 6,000 molecular properties across 16 biomedical modalities, including text, assay data, molecule structure, protein structure, images, multi-omics, biologics, clinical trial data, and pharmacokinetics. The system is designed to integrate diverse data sources and improve prediction accuracy as the model scales. Iambic initially launched Enchant in 2024. The company says its platform combines AI with automated chemistry and biology experimentation, and it previously discovered a novel drug candidate that advanced to clinical trials in approximately two years.

Intelligence360 News
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics
Nov 11th, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.